CTLA4 and urinary bladder carcinoma: High MYB expression is related to worse outcomes of anti-PD-1+ anti-CTLA4 treatment in melanoma, while received good outcomes of anti-PD-1 treatment in kidney cancer, melanoma, bladder cancer and glioblastoma.